The point-of-care opioid testing market size is projected to be worth US$ 450.9 million in 2023. The market is likely to surpass US$ 725.1 million by 2033 at a CAGR of 4.9% during the forecast period. The market for point-of-care opioid testing has been experiencing substantial growth and is expected to continue expanding. The increasing prevalence of opioid abuse, the opioid crisis, and the need for immediate and accurate detection are the key drivers of this market growth. The market size is influenced by factors such as regional variations in opioid abuse rates, regulatory policies, and healthcare infrastructure.
Point-of-care opioid testing find applications in diverse settings, including emergency departments, addiction treatment centers, law enforcement agencies, workplace drug testing programs, and community outreach programs. The ability to conduct immediate on-site testing without the need for specialized laboratory equipment makes these kits highly valuable in scenarios where rapid decision-making is critical.
Other Drivers Propelling the Demand for Point-of-Care Opioid Testing Market include:
Challenges for Companies /Manufacturers in the Point-of-Care Opioid Testing Market:
Opportunities in the Point-of-Care Opioid Testing Market Industry:
Latest Trends in the Point-of-Care Opioid Testing Market:
| Attributes | Details |
|---|---|
| Point-of-Care Opioid Testing Market Size (2023) | US$ 450.9 million |
| Point-of-Care Opioid Testing Market Projected Size (2033) | US$ 725.1 million |
| Value CAGR (2023 to 2033) | 4.9% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
From 2017 to 2022, the global point-of-care opioid testing market experienced a CAGR of 3.9%, reaching a market size of US$ 450.9 million in 2023.
From 2017 to 2022, the global point-of-care opioid testing industry witnessed significant growth as advancements in testing technologies have significantly contributed to the historic growth of the market. The development of point-of-care testing with improved accuracy, sensitivity, and speed has facilitated rapid screening and early detection of opioid use. These technological advancements have enhanced the convenience and accessibility of testing, leading to increased adoption and market growth.
Future Forecast for Point-of-Care Opioid Testing Market Industry:
Looking ahead, the global point-of-care opioid testing market industry is expected to rise at a CAGR of 4.9% from 2023 to 2033. During the forecast period, the market size is expected to reach US$ 725.1 million by 2033.
The point-of-care opioid testing industry is expected to continue its growth trajectory from 2023 to 2033, driven by increasing emphasis on patient-centered care and remote monitoring, there will be a growing demand for convenient and accessible testing options that can be performed in the comfort of one's home. Home-based testing kits and connected devices will empower individuals to monitor their opioid use, promote self-management, and facilitate remote consultations with healthcare providers.
| Country | The United States |
|---|---|
| Market Size (US$ million) by End of Forecast Period (2033) | US$ 227.4 million |
| CAGR % 2023 to End of Forecast (2033) | 4.2% |
The point-of-care opioid testing industry in the United States is expected to reach a market size of US$ 227.4 million by 2033, expanding at a CAGR of 4.2%. The opioid crisis remains a significant driver of the point-of-care opioid testing market in the United States. The increasing prevalence of opioid misuse and addiction has prompted healthcare providers, policymakers, and stakeholders to prioritize interventions and strategies to combat the crisis. Point-of-care opioid testing plays a crucial role in identifying opioid use, enabling early intervention, and monitoring treatment progress.
| Country | The United Kingdom |
|---|---|
| Market Size (US$ million) by End of Forecast Period (2033) | US$ 32.0 million |
| CAGR % 2023 to End of Forecast (2033) | 4.3% |
The point-of-care opioid testing industry in the United Kingdom is expected to reach a market value of US$ 32.0 million, expanding at a CAGR of 4.3% during the forecast period. Recent advancements in testing technologies have influenced the point-of-care opioid testing market in the UK. These advancements include the development of more accurate, sensitive, and user-friendly testing devices. Point-of-care opioid testing technologies, such as immunoassays, oral fluid tests, and urine tests, have become more reliable and accessible, supporting wider adoption in various healthcare settings.
| Country | China |
|---|---|
| Market Size (US$ million) by End of Forecast Period (2033) | US$ 54.7 million |
| CAGR % 2023 to End of Forecast (2033) | 6.4% |
The point-of-care opioid testing industry in China is anticipated to reach a market size of US$ 54.7 million, moving at a CAGR of 6.4% during the forecast period. The Chinese government has implemented initiatives and policies to combat substance abuse and improve public health outcomes. These initiatives include strengthening regulations on opioid medications, establishing rehabilitation centers, and promoting the use of point-of-care opioid testing in healthcare facilities. Government support and policies have been crucial drivers for the adoption and growth of the point-of-care opioid testing market in China.
| Country | Japan |
|---|---|
| Market Size (US$ million) by End of Forecast Period (2033) | US$ 39.9 million |
| CAGR % 2023 to End of Forecast (2033) | 6.2% |
The point-of-care opioid testing industry in Japan is estimated to reach a market size of US$ 39.9 million by 2033, thriving at a CAGR of 6.2%. Japan has seen increased research and development efforts in the field of point-of-care opioid testing. Academic institutions, research organizations, and healthcare companies are investing in the development of innovative testing methodologies, biomarkers, and data analysis algorithms. This driver fosters continuous innovation, advancements in testing technologies, and the potential for personalized medicine approaches in opioid addiction management.
| Country | South Korea |
|---|---|
| Market Size (US$ million) by End of Forecast Period (2033) | US$ 45.4 million |
| CAGR % 2023 to End of Forecast (2033) | 6.0% |
The point-of-care opioid testing industry in South Korea is expected to reach a market size of US$ 45.4 million, expanding at a CAGR of 6.0% during the forecast period. The South Korean government has implemented stricter regulations and monitoring measures for opioid medications. These regulations aim to prevent misuse, addiction, and illegal distribution of opioids. The increased focus on monitoring drives the adoption of point-of-care opioid testing as a tool to ensure compliance with regulations and enhance patient safety.
Principal Consultant
Test strips are expected to dominate the point-of-care opioid testing industry with a CAGR of 4.7% from 2023 to 2033. Test strips are available for different sample types, including urine, saliva, and blood. Urine is the most commonly used sample type for point-of-care opioid testing due to its ease of collection and high concentration of detectable substances. Saliva and blood samples may also be used in certain situations, such as in clinical laboratory settings or for specific testing requirements.
Multi-panel drug test kits are expected to dominate the point-of-care opioid testing industry with a CAGR of 5.2% from 2023 to 2033. Multi-panel kits allow for simultaneous testing of multiple drugs within a single device. Each drug panel on the test kit contains specific reagents or antibodies that react with the targeted drugs or their metabolites. When the sample is applied to the kit, it flows through the different panels, and if any of the targeted drugs are present, corresponding lines or color changes appear on the test result window.
Blood sample are expected to dominate the point-of-care opioid testing industry with a CAGR of 4.9% from 2023 to 2033. Blood samples provide a higher level of sensitivity and specificity compared to urine and saliva samples. The concentration of opioids and their metabolites in blood is generally higher and offers a more accurate representation of recent drug use. This makes blood testing particularly valuable in cases where precise quantification and detection of specific opioid compounds are required.
Forensic Laboratories is expected to dominate the point-of-care opioid testing industry with a CAGR of 5.4% from 2023 to 2033. Forensic laboratories play a crucial role in confirming preliminary point-of-care test results. Point-of-care tests provide rapid screening but may have limitations in terms of sensitivity and specificity. Forensic laboratories perform confirmatory testing to validate the presence of opioids and determine the precise concentration or level of opioids in a sample. This information is essential for legal proceedings, workplace incidents, and clinical decision-making.
The point-of-care opioid testing market is fiercely competitive, with many companies fighting for market dominance. To stay ahead of the competition in such a circumstance, essential players must develop effective conjugates.
Key Strategies Used by the Participants
Companies are investing in research & development to deliver product that improve efficiency, dependability, and cost-effectiveness. Product innovation allows businesses to differentiate themselves from their competition while also catering to the changing demands of their clients.
Key industry leaders frequently develop strategic partnerships and collaborations with other companies in order to harness their strengths and increase their market reach. Companies might also gain access to new technology and markets through such agreements.
The point-of-care opioid testing market is expanding rapidly in emerging regions such as China and India. Key firms are enhancing their distribution networks and developing local manufacturing facilities to increase their presence in these areas.
Mergers and acquisitions are frequently used by key players in the point-of-care opioid testing industry to consolidate their market position, extend their product range, and gain access to new markets.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Key Developments in the Point-of-care opioid testing Market:
The market is slated to attain US$ 725.1 million by 2033.
The growth potential of the point-of-care opioid testing market is 4.9% CAGR through 2033.
Widespread abuse of opioid and increasing efficiencies in the point-of-care opioid testing are propelling the market growth.
Avon Healthcare, Triveni Traders & Diagnostic Private Limited, and AdvaCare Pharma USA are the top market players.
Product development and expansion into emerging markets are key strategies consolidating the key players’ position.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends
4. Value Added Insights
4.1. Product Adoption / Usage Analysis
4.2. Product USP’s
4.3. Investment Feasibility Matrix
4.4. Brand Analysis
4.5. Value Chain Analysis
4.6. Regulatory Landscape
4.7. PESTEL Analysis
4.8. Porter’s Analysis
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global GDP Growth Outlook
5.1.2. Global Healthcare Expenditure Outlook
5.1.3. Global Drug of Abuse Testing Market Overview
5.2. Forecast Factors - Relevance & Impact
5.2.1. Key Player’s Historic Growth
5.2.2. Diagnosis Rate (%)
5.2.3. Favourable Government Regulations
5.2.4. Rising Demand for Opioid Testing
5.2.5. Technological Advancement in Opioid Test Kits
5.2.6. Increasing Incidence of Drug Abuse
5.2.7. Frequency of Product Approvals
5.3. Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. Global Market Volume (in Units) Analysis 2017 to 2022 and Forecast, 2023 to 2033
6.1. Historical Volume (in Units) Analysis, 2017 to 2022
6.2. Current and Future Volume (in Units) Projections, 2023 to 2033
6.2.1. Y-o-Y Growth Trend Analysis
7. Global Market - Pricing Analysis
7.1. Regional Pricing Analysis By Product
7.2. Pricing Break-up
7.2.1. Manufacturer Level Pricing
7.2.2. Distributor Level Pricing
7.3. Global Average Pricing Analysis Benchmark
7.4. Pricing Assumptions
8. Global Market Demand (in Value or Size in US$ Million) Analysis 2017 to 2022 and Forecast, 2023 to 2033
8.1. Historical Market Value (US$ Million) Analysis, 2017 to 2022
8.2. Current and Future Market Value (US$ Million) Projections, 2023 to 2033
8.2.1. Y-o-Y Growth Trend Analysis
8.2.2. Absolute $ Opportunity Analysis
9. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Product
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Million) and Volume (Units) Analysis By Product, 2017 to 2022
9.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Product, 2023 to 2033
9.3.1. Strips
9.3.2. Cassettes
9.3.3. Drug Test Dip Cards
9.4. Market Attractiveness Analysis By Product
10. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Modality
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Million) Analysis By Modality, 2017 to 2022
10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Modality, 2023 to 2033
10.3.1. Single Panel Drug Test Kits
10.3.2. Multi-panel Drug Test Kits
10.4. Market Attractiveness Analysis By Modality
11. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Sample
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Million) Analysis By Sample, 2017 to 2022
11.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Sample, 2023 to 2033
11.3.1. Saliva
11.3.2. Blood
11.3.3. Urine
11.3.4. Others
11.4. Market Attractiveness Analysis By Sample
12. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By End User
12.1. Introduction / Key Findings
12.2. Historical Market Size (US$ Million) Analysis By End User, 2017 to 2022
12.3. Current and Future Market Size (US$ Million) Analysis and Forecast By End User, 2023 to 2033
12.3.1. Hospitals
12.3.2. Diagnostics Laboratories
12.3.3. Forensic Laboratories
12.3.4. Home Care Settings
12.3.5. Others
12.4. Market Attractiveness Analysis By End User
13. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Region
13.1. Introduction
13.2. Historical Market Size (US$ Million) and Volume (Units) Analysis By Region, 2017 to 2022
13.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Region, 2023 to 2033
13.3.1. North America
13.3.2. Latin America
13.3.3. Europe
13.3.4. South Asia
13.3.5. East Asia
13.3.6. Oceania
13.3.7. Middle East and Africa
13.4. Market Attractiveness Analysis By Region
14. North America Market Analysis 2017 to 2022 and Forecast 2023 to 2033
14.1. Introduction
14.2. Historical Market Size (US$ Million) and Volume (Units) Analysis By Market Taxonomy, 2017 to 2022
14.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Market Taxonomy, 2023 to 2033
14.3.1. By Country
14.3.1.1. USA
14.3.1.2. Canada
14.3.2. By Product
14.3.3. By Modality
14.3.4. By Sample
14.3.5. By End User
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Product
14.4.3. By Modality
14.4.4. By Sample
14.4.5. By End User
14.5. Country Level Analysis & Forecast
14.5.1. USA Market Analysis
14.5.1.1. Introduction
14.5.1.2. Market Analysis and Forecast by Market Taxonomy
14.5.1.2.1. By Product
14.5.1.2.2. By Modality
14.5.1.2.3. By Sample
14.5.1.2.4. By End User
14.5.2. Canada Market Analysis
14.5.2.1. Introduction
14.5.2.2. Market Analysis and Forecast by Market Taxonomy
14.5.2.2.1. By Product
14.5.2.2.2. By Modality
14.5.2.2.3. By Sample
14.5.2.2.4. By End User
14.6. Market Trends
14.7. Key Market Participants - Intensity Mapping
14.8. Drivers and Restraints - Impact Analysis
15. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033
15.1. Introduction
15.2. Historical Market Size (US$ Million) and Volume (Units) Analysis By Market Taxonomy, 2017 to 2022
15.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Market Taxonomy, 2023 to 2033
15.3.1. By Country
15.3.1.1. Brazil
15.3.1.2. Mexico
15.3.1.3. Argentina
15.3.1.4. Rest of Latin America
15.3.2. By Product
15.3.3. By Modality
15.3.4. By Sample
15.3.5. By End User
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Product
15.4.3. By Modality
15.4.4. By Sample
15.4.5. By End User
15.5. Country Level Analysis & Forecast
15.5.1. Brazil Market Analysis
15.5.1.1. Introduction
15.5.1.2. Market Analysis and Forecast by Market Taxonomy
15.5.1.2.1. By Product
15.5.1.2.2. By Modality
15.5.1.2.3. By Sample
15.5.1.2.4. By End User
15.5.2. Mexico Market Analysis
15.5.2.1. Introduction
15.5.2.2. Market Analysis and Forecast by Market Taxonomy
15.5.2.2.1. By Product
15.5.2.2.2. By Modality
15.5.2.2.3. By Sample
15.5.2.2.4. By End User
15.5.3. Argentina Market Analysis
15.5.3.1. Introduction
15.5.3.2. Market Analysis and Forecast by Market Taxonomy
15.5.3.2.1. By Product
15.5.3.2.2. By Modality
15.5.3.2.3. By Sample
15.5.3.2.4. By End User
15.6. Market Trends
15.7. Key Market Participants - Intensity Mapping
15.8. Drivers and Restraints - Impact Analysis
16. Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033
16.1. Introduction
16.2. Historical Market Size (US$ Million) and Volume (Units) Analysis By Market Taxonomy, 2017 to 2022
16.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Market Taxonomy, 2023 to 2033
16.3.1. By Country
16.3.1.1. Germany
16.3.1.2. France
16.3.1.3. Italy
16.3.1.4. UK
16.3.1.5. Spain
16.3.1.6. Russia
16.3.1.7. BENELUX
16.3.1.8. Rest of Europe
16.3.2. By Product
16.3.3. By Modality
16.3.4. By Sample
16.3.5. By End User
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Product
16.4.3. By Modality
16.4.4. By Sample
16.4.5. By End User
16.5. Country Level Analysis & Forecast
16.5.1. Germany Market Analysis
16.5.1.1. Introduction
16.5.1.2. Market Analysis and Forecast by Market Taxonomy
16.5.1.2.1. By Product
16.5.1.2.2. By Modality
16.5.1.2.3. By Sample
16.5.1.2.4. By End User
16.5.2. France Market Analysis
16.5.2.1. Introduction
16.5.2.2. Market Analysis and Forecast by Market Taxonomy
16.5.2.2.1. By Product
16.5.2.2.2. By Modality
16.5.2.2.3. By Sample
16.5.2.2.4. By End User
16.5.3. Italy Market Analysis
16.5.3.1. Introduction
16.5.3.2. Market Analysis and Forecast by Market Taxonomy
16.5.3.2.1. By Product
16.5.3.2.2. By Modality
16.5.3.2.3. By Sample
16.5.3.2.4. By End User
16.5.4. UK Market Analysis
16.5.4.1. Introduction
16.5.4.2. Market Analysis and Forecast by Market Taxonomy
16.5.4.2.1. By Product
16.5.4.2.2. By Modality
16.5.4.2.3. By Sample
16.5.4.2.4. By End User
16.5.5. Spain Market Analysis
16.5.5.1. Introduction
16.5.5.2. Market Analysis and Forecast by Market Taxonomy
16.5.5.2.1. By Product
16.5.5.2.2. By Modality
16.5.5.2.3. By Sample
16.5.5.2.4. By End User
16.5.6. Russia Market Analysis
16.5.6.1. Introduction
16.5.6.2. Market Analysis and Forecast by Market Taxonomy
16.5.6.2.1. By Product
16.5.6.2.2. By Modality
16.5.6.2.3. By Sample
16.5.6.2.4. By End User
16.5.7. BENELUX Market Analysis
16.5.7.1. Introduction
16.5.7.2. Market Analysis and Forecast by Market Taxonomy
16.5.7.2.1. By Product
16.5.7.2.2. By Modality
16.5.7.2.3. By Sample
16.5.7.2.4. By End User
16.6. Market Trends
16.7. Key Market Participants - Intensity Mapping
16.8. Drivers and Restraints - Impact Analysis
17. South Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033
17.1. Introduction
17.2. Historical Market Size (US$ Million) and Volume (Units) Analysis By Market Taxonomy, 2017 to 2022
17.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Market Taxonomy, 2023 to 2033
17.3.1. By Country
17.3.1.1. India
17.3.1.2. Thailand
17.3.1.3. Indonesia
17.3.1.4. Malaysia
17.3.1.5. Rest of South Asia
17.3.2. By Product
17.3.3. By Modality
17.3.4. By Sample
17.3.5. By End User
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Product
17.4.3. By Modality
17.4.4. By Sample
17.4.5. By End User
17.5. Country Level Analysis & Forecast
17.5.1. India Market Analysis
17.5.1.1. Introduction
17.5.1.2. Market Analysis and Forecast by Market Taxonomy
17.5.1.2.1. By Product
17.5.1.2.2. By Modality
17.5.1.2.3. By Sample
17.5.1.2.4. By End User
17.5.2. Thailand Market Analysis
17.5.2.1. Introduction
17.5.2.2. Market Analysis and Forecast by Market Taxonomy
17.5.2.2.1. By Product
17.5.2.2.2. By Modality
17.5.2.2.3. By Sample
17.5.2.2.4. By End User
17.5.3. Indonesia Market Analysis
17.5.3.1. Introduction
17.5.3.2. Market Analysis and Forecast by Market Taxonomy
17.5.3.2.1. By Product
17.5.3.2.2. By Modality
17.5.3.2.3. By Sample
17.5.3.2.4. By End User
17.5.4. Malaysia Market Analysis
17.5.4.1. Introduction
17.5.4.2. Market Analysis and Forecast by Market Taxonomy
17.5.4.2.1. By Product
17.5.4.2.2. By Modality
17.5.4.2.3. By Sample
17.5.4.2.4. By End User
17.6. Market Trends
17.7. Key Market Participants - Intensity Mapping
17.8. Drivers and Restraints - Impact Analysis
18. East Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033
18.1. Introduction
18.2. Historical Market Size (US$ Million) and Volume (Units) Analysis By Market Taxonomy, 2017 to 2022
18.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Market Taxonomy, 2023 to 2033
18.3.1. By Country
18.3.1.1. China
18.3.1.2. Japan
18.3.1.3. South Korea
18.3.2. By Product
18.3.3. By Modality
18.3.4. By Sample
18.3.5. By End User
18.4. Market Attractiveness Analysis
18.4.1. By Country
18.4.2. By Product
18.4.3. By Modality
18.4.4. By Sample
18.4.5. By End User
18.5. Country Level Analysis & Forecast
18.5.1. China Market Analysis
18.5.1.1. Introduction
18.5.1.2. Market Analysis and Forecast by Market Taxonomy
18.5.1.2.1. By Product
18.5.1.2.2. By Modality
18.5.1.2.3. By Sample
18.5.1.2.4. By End User
18.5.2. Japan Market Analysis
18.5.2.1. Introduction
18.5.2.2. Market Analysis and Forecast by Market Taxonomy
18.5.2.2.1. By Product
18.5.2.2.2. By Modality
18.5.2.2.3. By Sample
18.5.2.2.4. By End User
18.5.3. South Korea Market Analysis
18.5.3.1. Introduction
18.5.3.2. Market Analysis and Forecast by Market Taxonomy
18.5.3.2.1. By Product
18.5.3.2.2. By Modality
18.5.3.2.3. By Sample
18.5.3.2.4. By End User
18.6. Market Trends
18.7. Key Market Participants - Intensity Mapping
18.8. Drivers and Restraints - Impact Analysis
19. Oceania Market Analysis 2017 to 2022 and Forecast 2023 to 2033
19.1. Introduction
19.2. Historical Market Size (US$ Million) and Volume (Units) Analysis By Market Taxonomy, 2017 to 2022
19.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Market Taxonomy, 2023 to 2033
19.3.1. By Country
19.3.1.1. Australia
19.3.1.2. New Zealand
19.3.2. By Product
19.3.3. By Modality
19.3.4. By Sample
19.3.5. By End User
19.4. Market Attractiveness Analysis
19.4.1. By Country
19.4.2. By Product
19.4.3. By Modality
19.4.4. By Sample
19.4.5. By End User
19.5. Country Level Analysis & Forecast
19.5.1. Australia Market Analysis
19.5.1.1. Introduction
19.5.1.2. Market Analysis and Forecast by Market Taxonomy
19.5.1.2.1. By Product
19.5.1.2.2. By Modality
19.5.1.2.3. By Sample
19.5.1.2.4. By End User
19.5.2. New Zealand Market Analysis
19.5.2.1. Introduction
19.5.2.2. Market Analysis and Forecast by Market Taxonomy
19.5.2.2.1. By Product
19.5.2.2.2. By Modality
19.5.2.2.3. By Sample
19.5.2.2.4. By End User
19.6. Market Trends
19.7. Key Market Participants - Intensity Mapping
19.8. Drivers and Restraints - Impact Analysis
20. Middle East and Africa Market Analysis 2017 to 2022 and Forecast 2023 to 2033
20.1. Introduction
20.2. Historical Market Size (US$ Million) and Volume (Units) Analysis By Market Taxonomy, 2017 to 2022
20.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Market Taxonomy, 2023 to 2033
20.3.1. By Country
20.3.1.1. GCC Countries
20.3.1.2. Türkiye
20.3.1.3. Northern Africa
20.3.1.4. South Africa
20.3.1.5. Rest of Middle East and Africa
20.3.2. By Product
20.3.3. By Modality
20.3.4. By Sample
20.3.5. By End User
20.4. Market Attractiveness Analysis
20.4.1. By Country
20.4.2. By Product
20.4.3. By Modality
20.4.4. By Sample
20.4.5. By End User
20.5. Country Level Analysis & Forecast
20.5.1. GCC Countries Market Analysis
20.5.1.1. Introduction
20.5.1.2. Market Analysis and Forecast by Market Taxonomy
20.5.1.2.1. By Product
20.5.1.2.2. By Modality
20.5.1.2.3. By Sample
20.5.1.2.4. By End User
20.5.2. Türkiye Market Analysis
20.5.2.1. Introduction
20.5.2.2. Market Analysis and Forecast by Market Taxonomy
20.5.2.2.1. By Product
20.5.2.2.2. By Modality
20.5.2.2.3. By Sample
20.5.2.2.4. By End User
20.5.3. Northern Africa Market Analysis
20.5.3.1. Introduction
20.5.3.2. Market Analysis and Forecast by Market Taxonomy
20.5.3.2.1. By Product
20.5.3.2.2. By Modality
20.5.3.2.3. By Sample
20.5.3.2.4. By End User
20.5.4. South Africa Market Analysis
20.5.4.1. Introduction
20.5.4.2. Market Analysis and Forecast by Market Taxonomy
20.5.4.2.1. By Product
20.5.4.2.2. By Modality
20.5.4.2.3. By Sample
20.5.4.2.4. By End User
20.6. Market Trends
20.7. Key Market Participants - Intensity Mapping
20.8. Drivers and Restraints - Impact Analysis
21. Market Structure Analysis
21.1. Market Analysis by Tier of Companies
21.2. Market Share Analysis of Top Players
21.3. Market Presence Analysis
22. Competition Analysis
22.1. Competition Dashboard
22.2. Branding and Promotional Strategies, By Key Players
22.3. Key Development Analysis
22.4. Competition Deep Dive
22.4.1. Avon Healthcare
22.4.1.1. Overview
22.4.1.2. Product Portfolio
22.4.1.3. Key Financials
22.4.1.4. Sales Footprint
22.4.1.5. SWOT Analysis
22.4.1.6. Strategy Overview
22.4.1.6.1. Marketing Strategy
22.4.1.6.2. Product Strategy
22.4.1.6.3. Channel Strategy
22.4.2. Triveni Traders & Diagnostic Private Limited
22.4.2.1. Overview
22.4.2.2. Product Portfolio
22.4.2.3. Key Financials
22.4.2.4. Sales Footprint
22.4.2.5. SWOT Analysis
22.4.2.6. Strategy Overview
22.4.2.6.1. Marketing Strategy
22.4.2.6.2. Product Strategy
22.4.2.6.3. Channel Strategy
22.4.3. AdvaCare Pharma USA
22.4.3.1. Overview
22.4.3.2. Product Portfolio
22.4.3.3. Key Financials
22.4.3.4. Sales Footprint
22.4.3.5. SWOT Analysis
22.4.3.6. Strategy Overview
22.4.3.6.1. Marketing Strategy
22.4.3.6.2. Product Strategy
22.4.3.6.3. Channel Strategy
22.4.4. BTNX Inc.
22.4.4.1. Overview
22.4.4.2. Product Portfolio
22.4.4.3. Key Financials
22.4.4.4. Sales Footprint
22.4.4.5. SWOT Analysis
22.4.4.6. Strategy Overview
22.4.4.6.1. Marketing Strategy
22.4.4.6.2. Product Strategy
22.4.4.6.3. Channel Strategy
22.4.5. Phamatech
22.4.5.1. Overview
22.4.5.2. Product Portfolio
22.4.5.3. Key Financials
22.4.5.4. Sales Footprint
22.4.5.5. SWOT Analysis
22.4.5.6. Strategy Overview
22.4.5.6.1. Marketing Strategy
22.4.5.6.2. Product Strategy
22.4.5.6.3. Channel Strategy
22.4.6. ADC
22.4.6.1. Overview
22.4.6.2. Product Portfolio
22.4.6.3. Key Financials
22.4.6.4. Sales Footprint
22.4.6.5. SWOT Analysis
22.4.6.6. Strategy Overview
22.4.6.6.1. Marketing Strategy
22.4.6.6.2. Product Strategy
22.4.6.6.3. Channel Strategy
22.4.7. Worldwide Medical Corporation
22.4.7.1. Overview
22.4.7.2. Product Portfolio
22.4.7.3. Key Financials
22.4.7.4. Sales Footprint
22.4.7.5. SWOT Analysis
22.4.7.6. Strategy Overview
22.4.7.6.1. Marketing Strategy
22.4.7.6.2. Product Strategy
22.4.7.6.3. Channel Strategy
22.4.8. Accu-Stat Diagnostics, Inc
22.4.8.1. Overview
22.4.8.2. Product Portfolio
22.4.8.3. Key Financials
22.4.8.4. Sales Footprint
22.4.8.5. SWOT Analysis
22.4.8.6. Strategy Overview
22.4.8.6.1. Marketing Strategy
22.4.8.6.2. Product Strategy
22.4.8.6.3. Channel Strategy
22.4.9. ACON Laboratories, Inc.
22.4.9.1. Overview
22.4.9.2. Product Portfolio
22.4.9.3. Key Financials
22.4.9.4. Sales Footprint
22.4.9.5. SWOT Analysis
22.4.9.6. Strategy Overview
22.4.9.6.1. Marketing Strategy
22.4.9.6.2. Product Strategy
22.4.9.6.3. Channel Strategy
22.4.10. Alere
22.4.10.1. Overview
22.4.10.2. Product Portfolio
22.4.10.3. Key Financials
22.4.10.4. Sales Footprint
22.4.10.5. SWOT Analysis
22.4.10.6. Strategy Overview
22.4.10.6.1. Marketing Strategy
22.4.10.6.2. Product Strategy
22.4.10.6.3. Channel Strategy
22.4.11. Innovacon, Inc.
22.4.11.1. Overview
22.4.11.2. Product Portfolio
22.4.11.3. Key Financials
22.4.11.4. Sales Footprint
22.4.11.5. SWOT Analysis
22.4.11.6. Strategy Overview
22.4.11.6.1. Marketing Strategy
22.4.11.6.2. Product Strategy
22.4.11.6.3. Channel Strategy
22.4.12. Amedica Biotech, Inc
22.4.12.1. Overview
22.4.12.2. Product Portfolio
22.4.12.3. Key Financials
22.4.12.4. Sales Footprint
22.4.12.5. SWOT Analysis
22.4.12.6. Strategy Overview
22.4.12.6.1. Marketing Strategy
22.4.12.6.2. Product Strategy
22.4.12.6.3. Channel Strategy
22.4.13. Branan Medical Corporation
22.4.13.1. Overview
22.4.13.2. Product Portfolio
22.4.13.3. Key Financials
22.4.13.4. Sales Footprint
22.4.13.5. SWOT Analysis
22.4.13.6. Strategy Overview
22.4.13.6.1. Marketing Strategy
22.4.13.6.2. Product Strategy
22.4.13.6.3. Channel Strategy
22.4.14. Biosite Inc
22.4.14.1. Overview
22.4.14.2. Product Portfolio
22.4.14.3. Key Financials
22.4.14.4. Sales Footprint
22.4.14.5. SWOT Analysis
22.4.14.6. Strategy Overview
22.4.14.6.1. Marketing Strategy
22.4.14.6.2. Product Strategy
22.4.14.6.3. Channel Strategy
22.4.15. UCP Biosciences, Inc
22.4.15.1. Overview
22.4.15.2. Product Portfolio
22.4.15.3. Key Financials
22.4.15.4. Sales Footprint
22.4.15.5. SWOT Analysis
22.4.15.6. Strategy Overview
22.4.15.6.1. Marketing Strategy
22.4.15.6.2. Product Strategy
22.4.15.6.3. Channel Strategy
22.4.16. TransMed Company
22.4.16.1. Overview
22.4.16.2. Product Portfolio
22.4.16.3. Key Financials
22.4.16.4. Sales Footprint
22.4.16.5. SWOT Analysis
22.4.16.6. Strategy Overview
22.4.16.6.1. Marketing Strategy
22.4.16.6.2. Product Strategy
22.4.16.6.3. Channel Strategy
22.4.17. Vitrosens Biotechnology
22.4.17.1. Overview
22.4.17.2. Product Portfolio
22.4.17.3. Key Financials
22.4.17.4. Sales Footprint
22.4.17.5. SWOT Analysis
22.4.17.6. Strategy Overview
22.4.17.6.1. Marketing Strategy
22.4.17.6.2. Product Strategy
22.4.17.6.3. Channel Strategy
22.4.18. Abbot
22.4.18.1. Overview
22.4.18.2. Product Portfolio
22.4.18.3. Key Financials
22.4.18.4. Sales Footprint
22.4.18.5. SWOT Analysis
22.4.18.6. Strategy Overview
22.4.18.6.1. Marketing Strategy
22.4.18.6.2. Product Strategy
22.4.18.6.3. Channel Strategy
22.4.19. clarity diagnostics
22.4.19.1. Overview
22.4.19.2. Product Portfolio
22.4.19.3. Key Financials
22.4.19.4. Sales Footprint
22.4.19.5. SWOT Analysis
22.4.19.6. Strategy Overview
22.4.19.6.1. Marketing Strategy
22.4.19.6.2. Product Strategy
22.4.19.6.3. Channel Strategy
22.4.20. Alcotec Company Limited
22.4.20.1. Overview
22.4.20.2. Product Portfolio
22.4.20.3. Key Financials
22.4.20.4. Sales Footprint
22.4.20.5. SWOT Analysis
22.4.20.6. Strategy Overview
22.4.20.6.1. Marketing Strategy
22.4.20.6.2. Product Strategy
22.4.20.6.3. Channel Strategy
23. Assumptions and Acronyms Used
24. Research Methodology
Explore Healthcare Insights
View Reports
Point-of-Care Opioid Testing Market
